12-01 :: January 2012
nanotimes
Companies Facts
T
he Board of Directors of AMCOL International Corporation (NYSE: ACO) has appointed Pa-
trick Carpenter as President of AMCOL‘s Environ- mental segment. Mr. Carpenter has been with the company for 20 years working within management roles for the Building Materials and Lining Technolo- gies businesses.
For the fourth quarter of 2011, AMCOL Internati- onal Corporation (NYSE: ACO) generated diluted earnings per share attributable to its shareholders from continuing operations of $0.43 per share versus a loss of $0.30 per share in the prior year‘s quarter. Excluding unusual items in Q4 2010, diluted ear- nings per share attributable to our shareholders was $0.21 per diluted share. Net sales increased 6.5% to $233.7 million for the 2011 fourth quarter, as com- pared to $219.4 million for the 2010 period. Gross profit increased 16.1% while gross margin increased 220 basis points to 26.6%. Operating profit increa- sed 63.8% with operating margin increasing by 300 basis points to 8.6%.
http://www.amcol.com
the Company’s workforce, right size capacity, and reduce operating costs in 2012. In addition, the Company will be terminating the lease of one of its U.S. facilities, which will result in a reduction in annual operating expenses related to this facility. AMRI expects that these cost-reduction initiatives will result in annual savings of approximately $10-11 million, including $7 million relating to the previous- ly announced cessation of R&D activities, and that
A
MRI (NASDAQ: AMRI) announced actions taken in the fourth quarter of 2011 to reduce
these savings will begin to be recognized in the first quarter of 2012.
http://www.amriglobal.com
Canadian Government to provide secure commu- nication systems that will be used to satisfy mobile application security requirements. The order was awarded to EMCON Emanation Control, part of API’s Secure Systems & Information Assurance (SSIA) division.
A
http://www.apitechnologies.com
(NASDAQ: ALNY), a leading RNAi therapeutics com- pany, and a nanomedicine company with develop- ment programs in RNAi and obesity, have entered into a collaboration and joint licensing agreement. Alnylam has granted Arrowhead a license under its intellectual property that enables the discovery, de- velopment, and commercialization of an RNAi thera- peutic targeting the hepatitis B virus (HBV). Alnylam is eligible to receive from Arrowhead milestone payments and royalties on sales of product resulting from the license. In addition, Alnylam has received a license from Arrowhead to utilize their Dynamic Polyconjugate (DPC) delivery technology for an RNAi therapeutic product. Alnylam expects to deploy this technology for an undisclosed target in its “Alnylam 5x15” pipeline which is focused on genetically de- fined targets and diseases. Arrowhead is eligible to
A
rrowhead Research Corporation, (NASDAQ: ARWR) and Alnylam Pharmaceuticals, Inc.
PI Technologies Corp. (NASDAQ: ATNY) has received a $3.5 million new order from the
15
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97